AZD3241 PET MSA Trial, Phase 2, Randomized,12 week Safety and Tolerability Trial with PET in MSA patients

Trial Identifier: D0490C00023
Sponsor: AstraZeneca
NCTID:: NCT02388295
Start Date: April 2015
Primary Completion Date: September 2016
Study Completion Date: September 2016

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Austria Innsbruck, Austria, 6020
Finland Turku, Finland, 20520
France Bordeaux Cedex, France, 33076
France Toulouse Cedex 9, France, 31059
Italy Salerno, Italy, 84131
Sweden Stockholm, Sweden, 141 86
United Kingdom London, United Kingdom, W12 0NN
United Kingdom London, United Kingdom, SE5 9RJ
United Kingdom Oxford, United Kingdom, OX3 9DU
United States of America, CA Stanford, CA, United States of America, 94305
United States of America, CT New Haven, CT, United States of America, 06520-8048
United States of America, FL Tampa, FL, United States of America, 33613
United States of America, MA Boston, MA, United States of America, 02215
United States of America, MI Ann Arbor, MI, United States of America, 48105-2945
United States of America, MN Rochester, MN, United States of America, 55905
United States of America, NY New York, NY, United States of America, 10016
United States of America, NY New York, NY, United States of America, 10032